Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients

PURPOSE: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GISTs). Imatinib, sunitinib and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Garner, Andrew P., Gozgit, Joseph M., Anjum, Rana, Vodala, Sadanand, Schrock, Alexa, Zhou, Tianjun, Serrano, Cesar, Eilers, Grant, Zhu, Meijun, Ketzer, Julia, Wardwell, Scott, Ning, Yaoyu, Song, Youngchul, Kohlmann, Anna, Wang, Frank, Clackson, Tim, Heinrich, Michael C., Fletcher, Jonathan A., Bauer, Sebastian, Rivera, Victor M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4233175/
https://ncbi.nlm.nih.gov/pubmed/25239608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1397
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge